Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply

Affiliations

¹ Department of Medical Oncology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France. Electronic address: patricia.pautier@gustaveroussy.fr.
² Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France.

Comment

Patricia Pautier et al. Lancet Oncol. 2022 Oct.

. 2022 Oct;23(10):e445.

doi: 10.1016/S1470-2045(22)00563-0.

¹ Department of Medical Oncology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France. Electronic address: patricia.pautier@gustaveroussy.fr.
² Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif 94805, France.

No abstract available

Conflict of interest statement

The declaration of interests for PP and BA remain the same as in the original Article. M-LT declares no competing interests.

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Sasi A, Pushpam D, Bakhshi S. Sasi A, et al. Lancet Oncol. 2022 Oct;23(10):e442. doi: 10.1016/S1470-2045(22)00546-0. Lancet Oncol. 2022. PMID: 36174623 No abstract available.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Chib S, Gogia A. Chib S, et al. Lancet Oncol. 2022 Oct;23(10):e443. doi: 10.1016/S1470-2045(22)00574-5. Lancet Oncol. 2022. PMID: 36174624 No abstract available.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Sütcüoğlu O, Özet A, Yazıcı O, Özdemir N. Sütcüoğlu O, et al. Lancet Oncol. 2022 Oct;23(10):e444. doi: 10.1016/S1470-2045(22)00547-2. Lancet Oncol. 2022. PMID: 36174625 No abstract available.